Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 18Colonic Neoplasms 4Rectal Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Solid Tumor Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Carcinoma 1Advanced/Metastatic Solid Tumors 1Advanced Gastric Cancer 1Adenocarcinoma 1

Interventions

Capecitabine 41Oxaliplatin 39Fluorouracil 29Leucovorin 23Radiotherapy 21Cetuximab 14Bevacizumab 14Irinotecan 13Nivolumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 9Surgical Procedures, Operative 8Folfox protocol 8Drug Therapy 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Chemoradiotherapy 7Biopsy 7trifluridine tipiracil drug combination 6Radiation 6tislelizumab 5sintilimab 5regorafenib 5dehydroftorafur 5X-Rays 5Surveys and Questionnaires 5Sigmoidoscopy 5Endoscopy 5Consolidation Chemotherapy 5spartalizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Trifluridine × 1 year × Clear all
NCT04104139 2026-04-15

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Roswell Park Cancer Institute

Phase 2 Completed
42 enrolled 12 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡